Lymphocyte Transfer for Cancer Therapy

Prerequisites for Efficacy and the Use of Long-Term Cultured T Lymphocytes
  • Martin A. Cheever
  • Philip D. Greenberg
  • Alexander Fefer


Tumor cells express surface antigens that can serve as targets for immunologic attack. It has long been known that T lymphocytes can respond to and specifically kill these cells in vitro. If such lymphocytes could be obtained in sufficient numbers, their adoptive transfer into a tumor-bearing host should provide berefit in tumor therapy.


Spleen Cell Donor Cell Adoptive Immunotherapy Syngeneic Tumor Chromium Release Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alaba, O., and Bernstein, I., 1978, Tumor-growth suppression in vivo: Cooperation between immune lymphoid cells sensitized in vitro and nonimmune bone marrow cells, J. Immunol. 120:1941–1946.PubMedGoogle Scholar
  2. Andrus, L., Atkinson, K., and Lafferty, K. J., 1982, Lethal effect of the intravenous injection of H-2 alloantigen-activated T cells, Clin. Immunol. 50:629–634.Google Scholar
  3. Berendt, M. J., and North, R. J., 1980, T-cell-mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor, J. Exp. Med. 151:69–80.PubMedGoogle Scholar
  4. Berendt, M. J., North, R. J., and Kirstein, D. P., 1978, The immunological basis of endotoxicinduced tumor regression. Requirement for T cell mediated immunity, J. Exp. Med. 148:1550–1559.PubMedGoogle Scholar
  5. Berenson, J. R., Einstein, A. B., and Fefer, A., 1975, Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: Requirement for T cells, J. Immunol. 115:234–238.PubMedGoogle Scholar
  6. Bernstein, I., 1977, Passive transfer of a systemic tumor immunity with cells generated in vitro by a secondary immune response to a syngeneic rat Gross-virus-induced lymphoma, J. Immunol. 118:122–128.PubMedGoogle Scholar
  7. Bernstein, I., Wright, P. W., and Cohen, E., 1976, Generation of cytotoxic lymphocytes in vitro: Response of immune rat spleen cells to a syngeneic Gross virus-induced lymphoma in mixed lymphocyte-tumor culture, J. Immunol. 116:1367–1372.PubMedGoogle Scholar
  8. Bhan, A. K., Reinisch, C. L., Levey, R. H., McCluskey, R. T., and Schlossman, S. F., 1975, T-cell migration into allografts, J. Exp. Med. 141:1210–1215.PubMedGoogle Scholar
  9. Bonnard, G. D., Yasaka, K., and Jacobson, D., 1979, Ligand-activated T cell growth factor-induced proliferation: Absorption of T cell growth factor by activated T cells, J. Immunol. 123:2704–2708.PubMedGoogle Scholar
  10. Borberg, H., Oettgen, H. F., Choudry, K., and Beathie, E. J., 1972, Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors, Int. J. Cancer 10:539–547.PubMedGoogle Scholar
  11. Borsos, T., Bast, R. C., Ohanian, S. H., Segerline, M., Zbar, B., and Rapp, H., 1976, Induction of tumor immunity by intratumoral chemotherapy, Ann. N.Y. Acad. Sci. 276:565–571.PubMedGoogle Scholar
  12. Burton, R. C., and Warner, N. L., 1977, In vitro induction of tumor-specific immunity. IV. Specific adoptive immunotherapy with cytotoxic T cells induced in vitro to plasmacytoma antigens, Cancer Immunol. Immunother. 2:91–99.Google Scholar
  13. Burton, R. C., Chism, S. E., and Warner, N. L., 1978, In vitro induction and expression of T-cell immunity to tumor-associated antiens, in: Contemporary Topics in Immunobiology, Volume 8 (N. L. Warner and M. D. Cooper, eds.), Plenum Press, New York, pp. 69–106.Google Scholar
  14. Cantor, H., and Boyse, E., 1977, Regulation of the immune response by T-cell subclasses, in: Contemporary Topics in Immunobioiogy, Volume 7 (O. Stutman, ed.), Plenum Press, New York, pp. 47–67.Google Scholar
  15. Cantor, H., McVay-Boudreau, L., Hugenberger, J., Naidorf, K., Shen, F. W., and Gershon, R. K., 1978, Immunoregulatory circuits among T-cell sets. II. Physiologic role of feedback inhibition in vivo: Absence in NZB mice, J. Exp. Med. 147:1116–1125.PubMedGoogle Scholar
  16. Celada, F., 1966, Quantitative studies of the adoptive immunological memory in mice. I. An age-dependent barrier to syngeneic transplantation, J. Exp. Med. 124:1–14.PubMedGoogle Scholar
  17. Chang, A. E., and Sugarbaker, P. H., 1979, Preferential homing of passively transferred T cells into skin allografts of mice, Transplantation 28:247–252.PubMedGoogle Scholar
  18. Chapdelaine, J. M., Plata, F., and Lilly, F., 1979, Tumors induced by murine sarcoma virus contain precursor cells capable of generating tumor-specific cytolytic T lymphocytes, J. Exp. Med. 149:1531–1536.PubMedGoogle Scholar
  19. Cheever, M. A., Kempf, R. A., and Fefer, A., 1977, Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro, J. Immunol. 119:714–718.PubMedGoogle Scholar
  20. Cheever, M. A., Greenberg, P. D., and Fefer, A., 1978, Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. II. Comparison of cells cultured with and without tumor to noncultured immune cells, J. Immunol. 121:2220–2227.PubMedGoogle Scholar
  21. Cheever, M. A., Greenberg, P. D., and Fefer, A., 1980, Specificity of adoptive chemoimmunotherapy of established syngeneic tumors, J. Immunol. 125:711–714.PubMedGoogle Scholar
  22. Cheever, M. A., Greenberg, P. D., and Fefer, A., 1981a, Adoptive chemoimmunotherapy of murine leukemia with cells secondarily sensitized in vitro and cells numerically expanded by culture with interleukin 2, in: Fundamental Mechanisms in Human Cancer Immunology (J. P. Saunders, ed.), International Cancer Symposium Committee, Elsevier/North Holland, New York, pp. 147–159.Google Scholar
  23. Cheever, M. A., Greenberg, P. D., and Fefer, A., 1981b, Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro, Cancer Res. 41:2658–2663.PubMedGoogle Scholar
  24. Cheever, M. A., Greenberg, P. D., and Fefer, A., 1981c. Chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: Effect of culture duration on therapeutic efficacy, J. Natl. Cancer Inst. 67:169–173.PubMedGoogle Scholar
  25. Cheever, M. A., Greenberg, P. D., and Fefer, A., 1981d, Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and non-specifically expanded by culture with interleukin 2, J. Immunol. 126:1318–1322.PubMedGoogle Scholar
  26. Cheever, M. A., Greenberg, P. D., Fefer, A., Gillis, S., 1982a, Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2, J. Exp. Med. 155:968–980.PubMedGoogle Scholar
  27. Cheever, M. A., Greenberg, P. D., Gillis, S., Fefer, A., 1982b, Specific adoptive therapy of murine leukemia with cells secondarily sensitized in vitro and expanded by culture with interleukin 2, in: The Potential Role of T Cells in CancerTherapy (A. Fefer and A. L. Goldstein, eds.), Raven Press, New York, pp. 127–146.Google Scholar
  28. Cheever, M. A., Greenberg, P. D., and Fefer, A., 1984, Potential for specific cancer therapy with immune T lymphocytes, J. Biol. Resp. Mod. (in press).Google Scholar
  29. Cohen, I. R., 1973, The recruitment of specific effector lymphocytes by antigen-reactive lymphocytes in cell-mediated autosensitization and allosensitization reactions, Cell. Immunol. 8:209–220.PubMedGoogle Scholar
  30. Dailey, M. O., Fathman, C. G., Butcher, E. C., Pillemer, E., and Weissman, I., 1982, Abnormal migration of T lymphocyte clones, J. Immunol. 128:2134–2136.PubMedGoogle Scholar
  31. Doig, D., and Chesebro, B., 1978, Antibody-induced loss of Friend virus leukemia cell surface antigens occurs during progression of erythroleukemia in F1 mice, J. Exp. Med. 148:1109–1129.PubMedGoogle Scholar
  32. Eberlein, T. J., Rosenstein, M., and Rosenberg, S. A., 1982, Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2, J. Exp. Med. 156:385–397.PubMedGoogle Scholar
  33. Einstein, A. B., Cheever, M. A., Fefer, A., 1976a, Induction of increased graft-versus-host disease by mouse spleen cells sensitized in vitro to allogeneic tumor, Transplantation 22:589–594.PubMedGoogle Scholar
  34. Einstein, A. B., Cheever, M. A., and Fefer, A., 1976b, The use of dimethyl myleran in adoptive chemoimmunotherapy of two murine leukemias, J. Natl. Cancer Inst. 56:609–613.PubMedGoogle Scholar
  35. Fass, L., and Fefer, A., 1972a, The application of an in vitro cytotoxicity test to studies of the effects of drugs on the cellular immune response in mice. I. Primary response, J. Immunol. 109:749–753.PubMedGoogle Scholar
  36. Fass, L., and Fefer, A., 1972b, Factors related to therapeutic efficacy in adoptive chemoimmunotherapy of a Friend virus-induced lymphoma, Cancer Res. 32:2427–2431.PubMedGoogle Scholar
  37. Fathman, C. G., and Kimoto, M., 1981, Studies utilizing murine T cell clones: Ir genes, Ia antigens and MLR stimulating determinants, Immunol. Rev. 54:57–79.PubMedGoogle Scholar
  38. Fathman, C. G., and Weissman, I. L., 1980, Production of alloreactive T-cell lymphomas, Nature 283:404–406.PubMedGoogle Scholar
  39. Fefer, A., 1970, Immunotherapy of primary Moloney sarcoma virus-induced tumors, Int. J. Cancer 5:327–337.PubMedGoogle Scholar
  40. Fefer, A., 1971, Adoptive chemoimmunotherapy of a Moloney lymphoma, Int. J. Cancer 8:364–373.PubMedGoogle Scholar
  41. Fefer, A., and Fass, L., 1976, Immunotherapeutic efficacy of lymphocytes from mice bearing lethal Friend leukemia (FBL-3), Proc. Am. Assoc. Cancer Res. 17:208 (abstr.).Google Scholar
  42. Fefer, A., McCoy, J. L., and Glynn, J. P., 1967, Antigenicity of a virus-induced murine sarcoma (Moloney), Cancer Res. 27:962–967.PubMedGoogle Scholar
  43. Fefer, A., Einstein, A. B., and Cheever, M. A., 1976a, Adoptive chemoimmunotherapy of cancer in animals: A review of results, principles and problems, Ann. N.Y. Acad. Sci. 277:492–504.PubMedGoogle Scholar
  44. Fefer, A., Einstein, A. B., Cheever, M. A., and Berenson, J. R., 1976b, Models for syngeneic adoptive chemoimmunotherapy of murine leukemias, Ann. N.Y. Acad. Sci. 276:573–583.PubMedGoogle Scholar
  45. Fernandez-Cruz, E., and Feldman, J. D., 1982, Immunotherapy of progressive tumors with T cell subsets, in: The Potential Role of T Cells in Cancer Therapy (A. Fefer and A. L. Goldstein, eds.), Raven Press, New York, pp. 53–63.Google Scholar
  46. Fernandez-Cruz, E., Halliburton, B., and Feldman, J. D., 1979, In vivo elimination by specific effector cells of an established syngeneic rat Moloney virus-induced sarcoma, J. Immunol. 123:1772–1777.PubMedGoogle Scholar
  47. Fernandez-Cruz, E., Woda, B. A., and Feldman, J. D., 1980, Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes, J. Exp. Med. 152:823–841.PubMedGoogle Scholar
  48. Fidler, I. J., and Kripke, M. L., 1980, Tumor cell antigenicity, host immunity, and cancer metastasis, Cancer Immunol. Immunother. 7:201–205.Google Scholar
  49. Friedman, H., Specter, S., Kamo, I., and Kateley, J., 1976, Tumor-associated immunosuppressive factors, Ann. N.Y. Acad. Sci. 276:417–430.PubMedGoogle Scholar
  50. Fujimoto, S., Greene, M. L, and Sehon, A. H., 1976, Regulation of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts, J. Immunol. 116:800–806.PubMedGoogle Scholar
  51. Fujiwara, H., Hamaoka, T., Shearer, G. M., Yamamoto, H., and Terry, W. D., 1980, The augmentation of in vitro and in vivo tumor-specific T cell-mediated immunity by amplifier T lymphocytes, J. Immunol. 124:863–869.PubMedGoogle Scholar
  52. Gillis, S., and Smith, K. A., 1977, Long-term culture of tumor-specific cytotoxic T cells, Nature 268:154–156.PubMedGoogle Scholar
  53. Gillis, S., Baker, P. E., Ruscetti, F. W., and Smith, K. A., 1978, Long-term culture of human antigen-specific cytotoxic T cell lines, J. Exp. Med. 148:1093–1098.PubMedGoogle Scholar
  54. Gillis, S., Mochizuki, D. Y., Conlon, P. J., Hefeneider, S. H., Ramthun, C. A., Gillis, A. E., Frank, M. B., Henney, C. S., and Watson, J. D., 1982, Molecular characterization of interleukin 2, Immunol. Rev. 63:167–209.PubMedGoogle Scholar
  55. Glasebrook, A. L., Sarmiento, M., Loken, M. R., Dialynas, D. P., Quintans, J., Eisenberg, L., Lutz, C. T., Wilde, D., and Fitch, F. W., 1981, Murine T lymphocyte clones with distinct immunological functions, Immunol. Rev. 54:225–266.PubMedGoogle Scholar
  56. Glaser, M., 1979, Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor-associated antigens by depletion of suppressor T cells with cyclophosphamide in mice, J. Exp. Med. 149:774–779.PubMedGoogle Scholar
  57. Gootenberg, J. E., Ruscetti, F. W., Mier, J. W., Gazdar, A., and Gallo, R. C., 1981, Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor, J. Exp. Med. 154:1403–1418.PubMedGoogle Scholar
  58. Green, W. R., Nowinski, R. C., and Henney, C. S., 1979, The generation and specificity of cytotoxic T cells raised against syngeneic tumor cells bearing AKR/Gross murine leukemia virus antigens, J. Exp. Med. 150:51–66.PubMedGoogle Scholar
  59. Greenberg, P. D., and Cheever, M. A., 1983, Reactivity of syngeneic and allogeneic grafted cells against tumors, in: Recent Advances in Bone Marrow Transplantation (R. P. Gale, ed.), Alan R. Liss, New York, pp. 255–279.Google Scholar
  60. Greenberg, P. D., Cheever, M. A., and Fefer, A., 1979, Suppression of the in vitro secondary response to syngeneic tumor and of in vivo tumor therapy with immune cells by cultureinduced suppressor cells, J. Immunol. 123:515–522.PubMedGoogle Scholar
  61. Greenberg, P. D., Cheever, M. A., and Fefer, A., 1980, Detection of early and delayed anti-tumor effects following curative adoptive chemoimmunotherapy of established leukemias, Cancer Res. 40:4428–4432.PubMedGoogle Scholar
  62. Greenberg, P. D., Cheever, M. A., and Fefer, A., 1981, Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+ 2- lymphocytes, J. Exp. Med. 154:952–963.PubMedGoogle Scholar
  63. Greenberg, P. D., Cheever, M. A., and Fefer, A., 1982, Prerequisites for successful adoptive immunotherapy: Nature of effector cells and role of H-2 restriction, in: ThePotential Role of T Cells in Cancer Therapy (A. Fefer and A. L. Goldstein, eds.), Raven Press, New York, pp. 31–51.Google Scholar
  64. Greene, M. I., 1980, The genetic and cellular basis of regulation of the immune response to tumor antigens, in: Contemporary Topics in Immunobiology, Volume 11 (N. L. Warner, ed.), Plenum Press, New York, pp. 81–116.Google Scholar
  65. Hardt, C., Röllinghoff, M, Pfizenmaier, K., Mosmann, H., and Wagner, H., 1981, Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo, J. Exp. Med. 154:262–274.PubMedGoogle Scholar
  66. Hellström, I., and Hellström, K. E., 1976, Specific sensitization of lymphocytes to tumor antigens by co-cultivation with peritoneal cells exposed to such antigens, Int. J. Cancer 17:748–754.PubMedGoogle Scholar
  67. Hellström, K. E., and Hellström, I., 1974, Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens, Adv. Immunol. 18:209–277.PubMedGoogle Scholar
  68. Henney, C. S., Okada, M., and Gillis, S., 1980, The cellular and antigenic requirements for IL-2 production in vitro, Behring Inst. Mitt. 67:26–35.Google Scholar
  69. Herberman, R. B., Aoki, T., Nunn, M., Laurin, D. H., Soares, N., Gazdar, A., Holden, H., and Chang, K. S. S., 1974, Specificity of 51Cr-release cytotoxicity of lymphocytes immune to murine sarcoma virus, J. Natl. Cancer Inst. 53:1103–1111.PubMedGoogle Scholar
  70. Hodes, R. J., and Hathcock, K. S., 1976, In vitro generation of suppressor cell cell activity: Suppression of in vitro induction of cell-mediated cytotoxicity, J. Immunol. 116:167–177.Google Scholar
  71. Hodes, R. J., Nadler, L. M., and Hathcock, K. S., 1977, Regulatory mechanisms in cell-mediated immune responses. III. Antigen-specific and non-specific suppressor activities generated during MLC, J. Immunol. 119:961–967.PubMedGoogle Scholar
  72. Inouye, H., Hank, J. A., Chardonnens, X., Segall, M., Alter, B. J., and Bach, F. H., 1980, Cloned primed-lymphocyte-test reagents in the dissection of HLA-D, J. Exp. Med. 152:143s-155s.PubMedGoogle Scholar
  73. Janeway, C. A., Sharrow, S. O., and Simpson, E., 1975, T cell populations with different functional activities, Nature 253:544–546.PubMedGoogle Scholar
  74. Kall, M. A., and Hellström, I., 1975, Specific stimulatory and cytotoxic effects of lymphocytes sensitized in vitro to either alloantigens or tumor antigens, J. Immunol. 114:1083–1088.PubMedGoogle Scholar
  75. Kedar, E., Raanan, Z., and Schwartzbach, M., 1978, In vitro induction of cell-mediated immunity to murine leukemia cells. VI. Adoptive immunotherapy in combination with chemotherapy of leukemia in mice, using lymphocytes sensitized in vitro to leukemia cells, Cancer Immunol. Immunother. 4:161–169.Google Scholar
  76. Klein, D. L., Brown, W., Cote, P., Garner, W., and Pearson, J. W., 1979, Chemoadoptive immunotherapy against a guinea-pig leukemia, Cancer Immunol. Immunother. 6:17–25.Google Scholar
  77. Lafferty, K. J., Warren, H. S., Woolnough, J. A., and Talmage, D. W., 1978, Immunological induction of T lymphocytes: Role of antigen and the lymphocyte costimulator, Blood Cells 4:395–404.PubMedGoogle Scholar
  78. Leclerc, J.-C., and Cantor, H., 1980a, T cell-mediated immunity to oncornavirus-induced tumors. I. Ly phenotype of precursor and effector cytolytic T lymphocytes, J. Immunol. 124:846–850.PubMedGoogle Scholar
  79. Leclerc, J.-C., and Cantor, H., 1980b, T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo, J. Immunol. 124:851–854.PubMedGoogle Scholar
  80. Lotze, M. T., Strausser, J. L, and Rosenberg, S. A., 1980a, In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells, J. Immunol. 124:2972–2978.PubMedGoogle Scholar
  81. Lotze, M. T., Line, B. R., Mathisen, D. J., and Rosenberg, S. A., 1980b, The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors, J. Immunol. 125:1487–1493.PubMedGoogle Scholar
  82. Loveland, B. E., Hogarth, P. M., Ceredig, R., and McKenzie, I. F. C., 1981, Cells mediating graft rejection in the mouse. I. Lyt-1 cells mediate skin graft rejection, J. Exp. Med. 153:1044–1057.PubMedGoogle Scholar
  83. MacDonald, H. R., Cerottini, J.-C., Ryser, J.-E., Maryanski, J. L., Taswell, C., Widmer, M. B., and Brunner, K. T., 1980, Quantitation and cloning of cytolytic T lymphocytes and their precursors, Immunol. Rev. 51:93–123.PubMedGoogle Scholar
  84. McKenzie, I. F. C., and Potter, T., 1979, Murine lymphocyte surface antigens, Adv. Immunol. 27:179–338.PubMedGoogle Scholar
  85. Mihich, E., 1969, Combined effects of chemotherapy and immunity against leukemia L1210 in DBAJ2 mice, Cancer Res. 29:848–854.PubMedGoogle Scholar
  86. Miller, R. A., Maloney, D. C., McKillop, J., and Levy, R., 1981, In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia, Blood 58:78–86.PubMedGoogle Scholar
  87. Mills, G. B., Carlson, G., and Paetkau, V., 1980, Generation of cytotoxic lymphocytes to syngeneic tumors by using co-stimulator (interleukin 2): In vivo activity, J. Immunol. 125:1904–1909.PubMedGoogle Scholar
  88. Mizel, S. B., and Farrar, J. J., 1979, Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors, Cell Immunol. 48:433–436.PubMedGoogle Scholar
  89. Nabholz, M., Engers, H. D., Collavo, D., and North, M., 1978, Cloned T cell lines with specific cytolytic activity, Curr. Top. Microbiol. Immunol. 81:176–187.PubMedGoogle Scholar
  90. Nakayama, E., Shiku, H., Stockert, E., Oettgen, H. F., and Old, L. J., 1979, Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera, Proc. Natl. Acad. Sci. USA 76:1977–1981.PubMedGoogle Scholar
  91. Nicolin, A., Vadlamudi, S., and Goldin, A., 1972, Antigenicity of L1210 leukemia sublines induced by drugs, Cancer Res. 32:653–657.PubMedGoogle Scholar
  92. North, R. J., Dye, E. S., and Mills, C. D., 1982, T cell-mediated negative regulation of concomitant antitumor immunity as an obstacle to adoptive immunotherapy of established tumors, in: The Potential Role of T Cell Subpopulations in Cancer Therapy (A. Fefer and A. L. Goldstein, eds.), Raven Press, New York, pp. 65–78.Google Scholar
  93. Orgad, S., and Cohen, I. R., 1974, Autoimmune encephalomyelitis: Activation of thymus lymphocytes against syngeneic brain antigens in vitro, Science 183:1083–1085.PubMedGoogle Scholar
  94. Perry, L. L., Dorf, M. E., Bach, B. A., Benacerraf, B., and Greene, M. L, 1980, Mechanisms of regulation of cell-mediated immunity: Anti-I-A alloantisera interfere with induction and expression of T-cell-mediated immunity to cell-bound antigen in vivo, Clin. Immunol. Immunopathol. 15:279–292.PubMedGoogle Scholar
  95. Plata, F., and Jongeneel, C. V., 1977, Characterization of effector lymphocytes associated with immunity to murine sarcoma virus (MSV)-induced tumors. II. Repeated stimulation and proliferation in vitro of specific cytolytic T lymphocytes, J. Immunol. 119:623–629.PubMedGoogle Scholar
  96. Plata, F., Cerottini, J. C., and Brunner, K. T., 1975, Primary and secondary in vitro generation of cytolytic T lymphocytes in the murine sarcoma virus system, Eur. J. Immunol. 5:227–233.PubMedGoogle Scholar
  97. Reinherz, E. L., and Schlossman, S. F., 1980, The differentiation and function of human T lymphocytes, Cell 19:821–827.PubMedGoogle Scholar
  98. Röllinghoff, M., and Wagner, H., 1973, Brief communication: In vivo protection against murine plasma cell tumor growth by in vitro activated syngeneic lymphocytes, J. Natl. Cancer Inst. 51:1317–1318.PubMedGoogle Scholar
  99. Rosenberg, S. A., and Terry, W. D., 1977, Passive immunotherapy of cancer in animals and man, Adv. Cancer Res. 25:323–388.PubMedGoogle Scholar
  100. Schreier, M. H., and Tees, R., 1980, Clonal induction of helper T cells: Conversion of specific signals into nonspecific signals, Int. Arch. Allergy Appl. Immunol. 61:227–237.PubMedGoogle Scholar
  101. Shaw, J., Caplan, B., Paetkau, V., Pilarski, L. M., Delovitch, T. L., and McKenzie, L F. C., 1980, Cellular origins of co-stimulator (IL 2) and its activity in cytotoxic T lymphocyte responses, J. Immunol. 124:2231–2239.PubMedGoogle Scholar
  102. Shiku, H., Takahashi, T., Bean, M. A., Old, L. J., and Oettgen, H. F., 1976, Ly phenotype of cytotoxic T cells for syngeneic tumor, J. Exp. Med. 144:1116–1120.PubMedGoogle Scholar
  103. Slease, R. B., Strong, D. M., Gawith, K. E., and Bonnard, G. D., 1981, Clinical effects of infusions into chimpanzees of primed autologous cultured T-cells, J. Natl. Cancer. Inst. 67:489–493.PubMedGoogle Scholar
  104. Small, M., and Trainin, N., 1976, Separation of populations of sensitized lymphoid cells into fractions inhibiting and fractions enhancing syngeneic tumor growth in vivo, J. Immunol. 117:292–297.PubMedGoogle Scholar
  105. Smith, H. G., Harmel, R. P., Hanna, M. G., Zwilling, B. S., Zbar, B. S., and Rapp, H. J., 1977, Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells, J. Natl. Cancer Inst. 58:1315–1321.PubMedGoogle Scholar
  106. Smith, K. A., Gillis, S., and Baker, P., 1979a, The inhibition of in vivo tumor growth by cytotoxic T cell lines, Proc. Am. Assoc. Cancer Res. 20:93 (abstr.).Google Scholar
  107. Smith, K. A., Gillis, S., Baker, P. E., McKenzie, D., and Ruscetti, F. W., 1979b, T cell growth factor mediated T cell proliferation, Ann. N.Y. Acad. Sci. 332:423–432.Google Scholar
  108. Sprent, J., and Miller, J. F. A. P., 1976, Fate of H2-activated T lymphocytes in syngeneic hosts. II. Residence in recirculating lymphocyte pool and capacity to migrate to allografts, Cell. Immunol. 21:303–313.PubMedGoogle Scholar
  109. Strausser, J. L., and Rosenberg, S. A., 1978, In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens, J. Immunol. 121:1491–1495.PubMedGoogle Scholar
  110. Stutman, O., Shen, F.-W., and Boyse, E. A., 1977, Ly phenotype of T cells cytotoxic for syngeneic mouse mammary tumors: Evidence for T cell interactions, Proc. Natl. Acad. Sci. USA 74:5667–5671.PubMedGoogle Scholar
  111. Ting, C. C., and Bonnard, G. D., 1976, Cell-mediated immunity to Friend virus-induced leukemia. IV. In vitro generation of primary and secondary cell-mediated cytotoxic responses, J. Immunol. 116:1419–1425.PubMedGoogle Scholar
  112. Ting, C. C., Kirchner, H., Rodrigues, D., Park, J. Y. and Herberman, R. B., 1976, Cell-mediated immunity to Friend virus-induced leukemia. III. Characteristics of secondary cell-mediated cytotoxic response, J. Immunol. 116:244–252.PubMedGoogle Scholar
  113. Ting, C. C., Rodrigues, D., and Igarashi, T., 1979, Studies of the mechanisms for the induction of in vivo tumor immunity. III. Recruitment of host helper cells by donor T cells in adoptive transfer of cell-mediated immunity, J. Immunol. 122:1510–1518.PubMedGoogle Scholar
  114. Treves, A. J., Cohen, I. R., and Feldman, M., 1975, Immunotherapy of lethal metastases by lymphocytes sensitized against tumor cells in vitro, J. Natl. Cancer Inst. 54:777–780.PubMedGoogle Scholar
  115. Treves, A. J., Cohen, I. R., Schechter, B., and Feldman, M., 1976a, In vivo effects of lymphocytes sensitized in vitro against tumor cells, Ann. N.Y. Acad. Sci. 276:165–175.PubMedGoogle Scholar
  116. Treves, A. J., Schechter, B., Cohen, I. R., and Feldman, M., 1976b, Sensitization of T lymphocytes in vitro by syngeneic macrophages fed with tumor antigens, J. Immunol. 116:1059–1064.PubMedGoogle Scholar
  117. Turk, J. L., Parker, D., and Poulter, L. W., 1972, Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide, Immunology 23:493–501.PubMedGoogle Scholar
  118. Vadlamudi, S., Padarathsingh, M., Bonmasser, E., and Goldin, A., 1971, Effect of combination treatment with cyclophosphamide and syngeneic or allogeneic spleen and bone marrow cells in leukemic (L1210) mice, Int. J. Cancer 7:160–166.PubMedGoogle Scholar
  119. Vose, B. M., and Bonnard, G. D., 1982, Human tumour antigens defined by cytotoxic and proliferative responses of cultured lymphoid cells, Nature 296:359–361.PubMedGoogle Scholar
  120. Wagner, H., and Röllinghoff, M., 1978, T-T cell interaction during in vitro cytotoxic allograft responses. I. Soluble products from activated Ly 1+ T cells trigger autonomously antigenprimed Ly 23 + T cells to cell proliferation and cytolytic activity, J. Exp. Med. 148:1523–1538.PubMedGoogle Scholar
  121. Wagner, H. C., Hardt, K., Heeg, K., Pfizenmaier, W., Solbach, R., Bartlett, H., Stockinger, H., and Röllinghoff, M., 1980a, T-T cell interaction during cytotoxic T lymphocyte (CTL) responses: T cell derived helper factor (interleukin 2) as a probe to analyze CTL responsiveness and thymic maturation of CTL progenitors, Immunol. Rev. 51:215–255.PubMedGoogle Scholar
  122. Wagner, H., Hardt, C., Heeg, M., Röllinghoff, M., and Pfizenmaier, K., 1980b, T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nuJnu mice, Nature 284:278–280.PubMedGoogle Scholar
  123. Watson, J., 1979, Continuous proliferation of murine antigen-specific helper T lymphocytes in culture, J. Exp. Med. 150:1510–1519.PubMedGoogle Scholar
  124. Weiden, P. L., Flournoy, N., Thomas, E. D., Prentice, R., Fefer, A., Buckner, C. D., and Storb, R., 1979, Antileukemic effect of graft-versus-host disease in human recipients of allogeneicmarrow grafts, N. Engl. J. Med. 300:1068–1073.PubMedGoogle Scholar
  125. Weiss, S., and Dennert, G., 1981, T cell lines active in the delayed-type hypersensitivity reaction (DTH), J. Immunol. 126:2031–2035.PubMedGoogle Scholar
  126. Zarling, J. M., and Bach, F. H., 1979, Continuous culture of T cells cytotoxic for autologous human leukemia cells, Nature 280:685–688.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Martin A. Cheever
    • 1
    • 2
  • Philip D. Greenberg
    • 1
    • 2
  • Alexander Fefer
    • 1
    • 2
  1. 1.Division of OncologyUniversity of Washington School of MedicineSeattleUSA
  2. 2.Fred Hutchinson Cancer Research CenterSeattleUSA

Personalised recommendations